Objective-To compare the costs of colorectal cancer (CRC) screening by two faecal occult blood tests (FOBl}-namely, Hemoccult (guaiac based) and reversed passive haemagglutination (RPHA) tests. RPHA was interpreted according to two positivity thresholds (+ or +1-).
Abstract
Objective-To compare the costs of colorectal cancer (CRC) screening by two faecal occult blood tests (FOBl}-namely, Hemoccult (guaiac based) and reversed passive haemagglutination (RPHA) tests. RPHA was interpreted according to two positivity thresholds (+ or +1-).
Methods-Attenders
performed both tests. Subjects with a positive FOBT test were invited to have a complete exploration of the colon. The total costs for every 10 000 screened subjects and costs for each unit of result (screened subject, or patient with adenomals or cancer detected) were calculated for both tests. Results-8353 subjects were enrolled. A total of 2109 repeated screening after two years. RPHA(+ and +1-) showed the highest and RPHA(+) the lowest positivity rate at first screening. The Hemoccult positivity rate was highest at repeat screening. Total costs of screening by RPHA(+ and +1-) were highest as this method had the highest recall rate. Screening by RPHA(+) was the least costly. Costs for each screened subject were highest for RPHA(+ and +1-) and lowest for RPHA(+). Costs for each cancer detected were lowest for RPHA(+) and highest for Hemoccult or RPHA(+ and +1-) in subjects aged> 49 or < 50, respectively. Costs for subjects with detected adenomals of> 9 mm were lowest for RPHA(+ and +1-) and highest for Hemoccult. At repeat screening total costs of RPHA(+ and +1-) were lower than at first screening, whereas for each subject with cancer or adenoma/s costs were increased. Conclusions-Our data confirm that screening by RPHA is more cost effective than by Hemoccult. Evidence on the efficacy of screening by faecal occult blood testing (FOBT) in reducing colorectal cancer (CRC) mortality has been recently provided by several randomised'" or case-control studies. >-9 Although there are differences in the designs of randomised or case-control studies, overall evidence supports the efficacy of annual or biennial screening by unhydrated or rehydrated guaiac based or immunochemical tests and seems sufficient to support the implementation of population based programmes as a current health policy. For such a programme the optimal screening procedures need to be defined-namely, the choice of (a) FOBT assays (guaiac or immunochemical; unhydrated or rehydrated guaiac test); (b) sampling modalities (three day guaiac testing or one day immunochemical testing); (c) screening frequency (annual or biennial). All these alternatives have been used in screening programmes that were effective in reducing CRC mortality, but each of them is associated with a different sensitivity and specificity level that is likely to affect the size of the protective effect of screening and costs. To optimise screening cost effectiveness it is thus urgent to compare the performances and the costs of different strategies.
We recently reported a comparative study of three day rehydrated guaiac testing and one day immunochemical testing using reversed passive haemagglutination (RPHA) according to two positivity thresholds." Immunochemical testing by RPHA was more accurate than guaiac testing, and screening by RPHA seemed to provide more protection. The present study aims at evaluating the costs of one day RPHA testing (Hemeselect, Smith Kline Diagnostics, Palo Alto, CA, USA; Immudia Hem SP, Fujirebio Inc, Tokyo, Japan) and three day rehydrated guaiac testing (Hemoccult II, Smith Kline Diagnostics, Palo Alto, CA, USA) in the same population.
Patients and methods
The features of the group studied and the study protocol were reported previously. 10 Briefly, subjects aged 40-70 years living in six municipalities (24 282 inhabitants aged 40-70) in the province of Florence were enrolled in the study and underwent a double FOBT screening investigation. Screening with the double FOBT protocol was repeated after two years only in two of the six municipalities (7982 subjects aged 40-70). Overall mean compliance in the course of our study was 38.7%.
In this study subjects undergoing the double FOBT protocol at their first screening examination were eligible provided that both tests had been completed. Subjects previously Attenders were asked to collect faeces samples; Hemoccult kits were used on three consecutive bowel movements and RPHA kits on the first bowel movement only. Subjects with both Hemoccult and RPHA negative tests were invited to repeat screening after two years. Subjects with a positive Hemoccult or a positive(+)/borderline(+/-) RPHA test, or both, were invited to undergo pancolonoscopy or a combination of left colonoscopy and double contrast barium enema when pancolonoscopy was not possible.
Costs were analysed to compare the total costs and costs for each unit of result (namely screened subject, or patient with adenoma or cancer) according to the three testing modalities. Costs were calculated for 10 000 invited subjects, assuming attendance rates of 38.7%, which is the attendance we had found. To assess the effect of differing compliance levels, costs were also calculated assuming an attendance rate of 77.4% (double that observed) and the same positivity and detection rates as seen in our setting.
The programme was divided into three phases: recruitment, screening, and assessment.
For the first two phases all relevant resources consumed by the programme were listed and measured, thus obtaining the actual costs for each phase. The quantification of each resource was carried out according to reference indicators. If a single resource was jointly used (for example, most of the staff involved) the resource percentage attributable to the screening programme was apportioned. 143 volunteers or external collaborators was estimated as the cost of employees in the same job for the same time. General expenses were calculated by dividing the total expense of our centre by the percentage of the total area currently occupied by the FOBT programme. The cost of the building was based on market rental prices. Costs for the recruitment phase include the resources for general organisation and direction of the programme. Costs were expressed in American dollars based on an exchange rate oUl to 1550 Italian liras.
The overall cost of Hemoccult kits (for faeces collection and development) was $3. The RPHA test consists of a collection and a reagent kit. Costs for one determination ranged between $0.5 and $0.9 for the former, and between $1 and $3.9 for the latter depending on the manufacturer. The lower costs were considered in this analysis.
To calculate the costs for the assessment phase (being performed by our endoscopists in hospital services) we used the National tariffs of the Ministry of Health (applicable at 22 July 1996). The tariffs set the costs of pancolonoscopy as $77.5, left colonoscopy $46.5, endoscopic polipectomy (independent of the number of polyps) $121, and biopsy $32. The costs for double contrast barium enema were set at $114 and for pathological examination for single or multiple determinations at $17 and $58 respectively.
In a sensitivity analysis an additional evaluation of the costs of the assessment phase was made according to the estimates of the mean costs of endoscopic examinations and treatments carried out by a working group of the Italian Society of Digestive Endoscopy (SIED"). According to this source costs of pancolonoscopy were set at $177.1, left colonoscopy $98.3, endoscopic polipectomy (per single polyp) $39, and biopsy $48.
Costs for pathological examinations and for double contrast barium enemas were considered constant in the sensitivity analysis as were the organisational costs (recall of patients, general management) of the assessment phase.
Results
From March 1992 to September 1995, 8353 subjects were recruited in this study (3887 men, mean age 54.2; 2509 over the age of 49; 4466 women, mean age 54.3, 2906 older than 49).
Repeat screening of 21 09 subjects (991 men, mean age 55.4, 709 over the age of 49; 1118 women, mean age 55.4 years, 802 older than 49) was carried out after two years according to the double FOBT protocol.
The positivity rates, positive predictive values for cancer or adenomas, and specificity of each test were analysed and compared as in a previous report. 10 Table 1 shows the first screening results according to age.
Hemoccult, RPHA(+ and +/-), and RPHA(+) detected 16, 22, and 18 cancers respectively. All of the 13 Dukes's A carcinomas were detected by RPHA(+ and +/-). Hemoccult and RPHA(+) detected six and A, one Dukes's B) in two subjects older than 49. All cancers detected at repeat screening were surgically treated. Table 3 gives details of the diagnostic protocol according to single tests and screening round in the overall series. Table 4 reports the estimated costs of an FOBT screening programme in a group of 10 000 subjects according to FOBT type, programme phase, population age, and screening round. In this table costs for the assessment phase were calculated according to the ministerial and the SIED tariffs. At first screening round RPHA(+ and +/-) was the most costly as the higher recall rate resulted in the highest cost for the assessment phase. RPHA(+) was the least expensive test in all programme phases. Hemoccult was in an intermediate position for total and assessment costs but was the most costly test for the screening phase. At repeat screening and in subjects aged 40-49 the total costs were lower than at the first screening owing to the lower positivity and recall rate. When SlED estimates are used rather than ministerial tariffs the overall assessment costs at first screening are increased by about 25%. Table 5 reports the estimated costs for each unit of result-namely, screened subject or patient with detected cancer or adenoma/s, according to FOBT type, population age, screening round, and assumed tariffs. At first screening RPHA(+ and +/-) had the highest cost for each screened subject and RPHA(+) the lowest one. Hemoccult showed the highest costs for each subject with detected cancer or adenoma/s; this was independent of the size of the largest adenoma. RPHA(+) had the lowest cost for detected cancer, whereas RPHA(+ and +/-) had the lowest cost for each subject with adenoma/s (independent of size). Costs for each subject screened decreased at the second round or in younger subjects. The cost for each subject with cancer or adenoma/s, however, increased at the second round and for younger subjects.
When SlED estimates for endoscopic costs were considered instead of national tariffs, nine Dukes's A cancers respectively. Curative polipectomy with no need for further surgery was obtained in two patients with a positive Hemoccult test, and in six with a positive (+) RPHA test. Table 2 reports the results of repeat screening according to age.
Three cancers were detected at repeat screening. All of them were Hemoccult negative; two were RPHA(+); one was RPHA (+/-). One cancer (Dukes's A) was diagnosed in a 49 year old subject, and two (one Dukes's costs for each screened subject or for each subject with detected cancer or adenoma/s increased by 16%, 17%, or 10% for Hemoccult, RPHA(+ and +/-), or RPHA(+) respectively in subjects aged 50-70 at first screening. SlED estimates of assessment costs caused smaller increases of costs at first screening in subjects aged 40-49 and an increase of 11% at repeat screening. Doubling the attendance rates (77.4% v 38.7%) reduces costs for each screened subject or for each detected cancer or adenoma/s at first screening by one fifth for Hemoccult or RPHA(+ and +/-) or by one quarter for RPHA(+) in subjects aged 50-70. The corresponding reduction of costs at repeat screening is about 25%. The most important determinant of cost difference is the recruitment cost for each screened subject, estimated at $7.8 or $4 when the lower or the higher compliance levels are considered respectively.
In tables 4 and 5 the lower RPHA costs were considered. If the higher costs had been assumed this would have increased screening or total costs by 38.1 % or 8.4% respectively.
Discussion
In this study we have compared the total costs and costs for each unit of result for the rehydrated Hemoccult test with those for one day RPHA tests, the latter being interpreted according to two different positivity thresholds. We have recently reported that the RPHA test is better than the Hemoccult test. 10 In fact when a higher positivity threshold was adopted (+), the RPHA positivity rate was markedly lower than that for Hemoccult and an improvement in specificity for cancer and in positive predictive value for cancer and adenomas was obtained with no corresponding reduction in the detection rate for cancer and adenomas >9 mm.
When a lower positivity threshold (+ and +/-) of RPHA was considered, the positivity rate at first screening was markedly higher and the specificity markedly lower than for Hemoccult. Despite such an increase of referral rate to colonoscopy the positive predictive value for cancer or adenomas, or both, was comparable with that of Hemoccult, and a larger number of cancers (particularly early stages ones) and adenomas were detected. These observations indicate the higher efficacy of screening by RPHA in reducing CRC mortality and incidence.
The results of repeat double FOBT screening are influenced by the different sensitivity levels of immunochemical and guaiac tests at first screening. In fact, the excess of cancers or adenomas detected by RPHA(+ and +/-) and not by the other two tests at first screening might have been detected by the two less sensitive FOBT types at repeat screening if screening by single tests had been performed. Despite the low detection rate, the Hemoccult positivity rate was higher than that of RPHA(+) or RPHA(+ and +/-) in 50-70 year old subjects, probably owing to false positive results of alimentary origin, with a negative impact on specificity. In view of this and owing to the low 145 detection rate, we decided not to calculate separately the costs of repeat screening by Hemoccult or RPHA(+).
Our cost analysis is based on the measurement of real costs for the recruitment and the screening phases. The costs of these phases (particularly of the recruitment phase) are strongly influenced by compliance. In our model we assumed a compliance of 38.7%, which is the compliance measured in the course of our study and is close to the actual attendance rates in our screening programme. It might be predicted that one day RPHA screening would increase compliance as there is no dietary restriction and a shorter period is required for faeces collection. With higher compliance rates, costs for each screened subject or each detected cancer or adenoma/s would be lower, though a great improvement in compliance would be needed to lower total costs markedly.
Costs of the assessment phase, with the exception of general organisational expenses, were determined according to Ministry of Health tariffs or SlED estimates. SlED estimates of costs for diagnostic colonoscopy are much higher than ministerial tariffs. The reverse is true for polypectomy. In addition, different criteria for calculation of costs or tariffs for polypectomy are used depending on which source is considered as SlED costs are determined according to the number of polyps whereas ministerial tariff is independent of this. Nevertheless, if national tariffs are used this permits easier comparison of costs between different screening options in different centres according to each test performance.
In CRC screening, assessment accounts for one third to one half of the total costs, which is unlike costs for other cancer screenings (breast, cervix). To optimise cost effectiveness it is important that the screening test is efficient as the costs of management of subjects with a positive FOBT are high.
Screening by an RPHA test may be more expensive or less expensive than screening with rehydrated Hemoccult depending on whether the lower or the higher threshold is adopted. However, irrespective of the adopted positivity criterion, the cost for each subject with a detected neoplastic lesion is lower for RPHA than for Hemoccult, RPHA(+) showing the lowest cost for each detected cancer, and RPHA(+ and +/-) the lowest cost for each subject with detected adenoma/so At repeat screening RPHA(+ and +/-) costs for each detected neoplasm are almost doubled, probably owing to the low prevalence of cancer or adenomas.
Our analysis confirms that screening for CRC under the age of 50 is not cost effective. Owing to the very low prevalence of CRC or adenomas under the age of 50, the costs for each detected cancer or adenoma/s at first screening were almost double those for older subjects. Cost analysis at repeat screening is not reliable as it is based on a single detected adenoma in subjects aged less than 50.
Our data confirm that screening for CRC by an immunochemical FOBT based on RPHA is more cost effective than guaiac testing. The
